Health Care

Gilead to buy Immunomedics in $21B deal

Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for $21 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the companies said on Sunday in a statement.

Oxford, AstraZeneca resume coronavirus vaccine trial

Oxford University says trials of a coronavirus vaccine that it is developing with pharmaceutical company AstraZeneca will resume, days after being paused due to a reported side-effect in a patient in the U.K.